Baker Bros. Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Baker Bros. Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-151,329	Closed	-$2.57M	–	89
2024 Q4	$2.57M	Hold	151,329	–	–	0.03%	82
2024 Q3	$3.51M	Hold	151,329	–	–	0.04%	74
2024 Q2	$3.68M	Buy	+151,329	New	+$4.59M	0.05%	74
2017 Q1	–	Sell	-333,766	Closed	-$4.91M	–	123
2016 Q4	$4.91M	Hold	333,766	–	–	0.05%	64
2016 Q3	$5.77M	Hold	333,766	–	–	0.05%	66
2016 Q2	$10.5M	Hold	333,766	–	–	0.11%	52
2016 Q1	$8.86M	Hold	333,766	–	–	0.09%	60
2015 Q4	$14.7M	Buy	333,766 +99,499	+42%	+$4.48M	0.12%	54
2015 Q3	$9.9M	Sell	234,267 -21,429	-8%	-$1.13M	0.09%	62
2015 Q2	$11.7M	Hold	255,696	–	–	0.1%	59
2015 Q1	$10.1M	Buy	255,696 +214,286	+517%	+$9.43M	0.08%	56
2014 Q4	$1.08M	Buy	+41,410	New	+$1.32M	0.01%	114

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Baker Bros. Advisors's ARCT Position: Q1 2025 in Review

Baker Bros. Advisors sold out of Arcturus Therapeutics (ARCT) in Q1 2025, closing a stake of 151,329 shares — an estimated $2.57M sold.

Baker Bros. Advisors first reported a position in ARCT in Q4 2014 and held it in 12 quarters. The position peaked at $14.7M in Q4 2015. 144 funds tracked by Wall St. Rank hold ARCT as of Q1 2025.

Baker Bros. Advisors reported no remaining Arcturus Therapeutics position as of Q1 2025 after selling out during the quarter.
Baker Bros. Advisors sold 151,329 Arcturus Therapeutics shares in Q1 2025, an estimated $2.57M.
Baker Bros. Advisors first reported a position in Arcturus Therapeutics in Q4 2014 and held it in 12 quarters.
Baker Bros. Advisors's Arcturus Therapeutics position peaked at $14.7M in Q4 2015.
144 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2025.

Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.